Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Interventional Cardiology Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 176
ISBN Number not applicable
Product Code GMD02909

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Interventional Cardiology Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Interventional Cardiology device manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Interventional Cardiology market categories - Coronary Stent,Cardiac Catheter,PTCA Balloon,Arteriotomy Closure Devices,Coronary Guidewire
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Interventional Cardiology market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Interventional Cardiology Clinical Trials
    • 2.1 Interventional Cardiology Clinical Trial By Equipment Type
    • 2.2 Interventional Cardiology Clinical Trials By Trial Phase and Trial Status
    • 2.3 Interventional Cardiology Pipeline Products By Development Stage
    • 2.4 Interventional Cardiology Pipeline Products By Therapy Area
    • 2.5 Interventional Cardiology Pipeline Products By News Summary
    • 2.6 Interventional Cardiology TAXUS Element Paclitaxel-Eluting Coronary Stent System
      • 2.6.1 A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
      • 2.6.2 A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
      • 2.6.3 A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.1.2 Jun 09, 2009: AngioScore's AngioSculpt Scoring Balloon Catheter Receives Japanese Approval For Peripheral Indications
      • 3.1.3 Jun 04, 2009: Cardiogenesis Corporation Presents Clinical Results Of PHOENIX Combination TMR Plus Stem Cell Delivery System At The International Society of Minimally Invasive Cardiothoracic Surgeons Annual Meeting
      • 3.1.4 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.1.5 Jun 02, 2009: Cook Medical Releases Z-TRAK PLUS Delivery System
      • 3.1.6 Jun 01, 2009: Prescient Medical Announces SECRITT I Trial Results For vProtect Luminal Shield
      • 3.1.7 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.1.8 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.1.9 May 21, 2009: CPC Of America Announces Patent Filing For Synthetic Sealant For The MedClose Vascular Closure System (VCS)
      • 3.1.10 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.1.11 May 19, 2009: Boston Scientific Announces Launch Of Third-Generation Platinum Chromium Drug-Eluting Stent In Select Markets
      • 3.1.12 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.1.13 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.1.14 May 19, 2009: InfraReDx Combined Near-Infrared Spectroscopy And Ultrasound Imaging Catheter First Uses In Coronary Patients
      • 3.1.15 May 19, 2009: Invatec Unveils IN.PACT Falcon Coronary Drug-Eluting Balloon At EuroPCR
      • 3.1.16 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.1.17 May 14, 2009: Medtronic Announces The Completion Of Enrollment In RESOLUTE International Trial
      • 3.1.18 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.1.19 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.1.20 Apr 28, 2009: ITGI Medical, Ltd Receives HUD (Humanitarian Use Device) Designation To Over And Under And Aneugraft Pericardium Covered Stents From FDA
      • 3.1.21 Apr 22, 2009: OrbusNeich Presents Results Of Genous Bio-Engineered R Stent In Higher Risk Patients
      • 3.1.22 Apr 09, 2009: US FDA Grants Pre-Market Approval For NMT Medical's STARFlex
      • 3.1.23 Apr 09, 2009: ZEST Clinical Data Shows Better Clinical Outcomes Compare To TAXUS LIBERTE And ENDEAVOR Stents
      • 3.1.24 Apr 07, 2009: NMT Medical Presents Update On CLOSURE I Clinical Trial
      • 3.1.25 Mar 31, 2009: Medtronic Announces International Market Release Of Driver Sprint RX Coronary Stent System
      • 3.1.26 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.1.27 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.1.28 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.1.29 Mar 28, 2009: Thrombus Aspiration With Medtronic's Export Catheter May Improve Outcomes For Heart Attack Patients
      • 3.1.30 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.1.31 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.32 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.33 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.1.34 Mar 11, 2009: BridgePoint Medical Announces First US Clinical Case Completion Using CrossBoss And Stingray Devices In CTO Angioplasty Procedure
      • 3.1.35 Mar 10, 2009: Abbott Introduces VOYAGER NC Coronary Balloon Catheter
      • 3.1.36 Mar 10, 2009: CPC Develops PEG Sealants For MedClose Vascular Closure System
      • 3.1.37 Mar 06, 2009: Stereotaxis's NAVISTAR RMT THERMOCOOL Catheter Performs Successfully In The Cardiac Ablation Procedures
      • 3.1.38 Mar 04, 2009: Micell Technologies To Showcase Its Rapid Absorption Polymer DES System At CRT 2009
      • 3.1.39 Mar 04, 2009: Prescient Medical Announces Milestone Achievement In Clinical Studies Of vProtect Luminal Shield
      • 3.1.40 Mar 03, 2009: Texas Cardiac Arrhythmia Institute First To Use Biosense Webster's NaviStar RMT ThermoCool Catheter
    • 3.2 Product Approvals
      • 3.2.1 Jun 09, 2009: AngioScore's AngioSculpt Scoring Balloon Catheter Receives Japanese Approval For Peripheral Indications
      • 3.2.2 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.2.3 Apr 28, 2009: ITGI Medical, Ltd Receives HUD (Humanitarian Use Device) Designation To Over And Under And Aneugraft Pericardium Covered Stents From FDA
      • 3.2.4 Apr 09, 2009: US FDA Grants Pre-Market Approval For NMT Medical's STARFlex
      • 3.2.5 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.2.6 Feb 27, 2009: Biosense Webster Announces FDA Approval For Magnetically Steered Irrigated Tip Cardiac Catheter For Treatment Of Irregular Heart Rhythms
      • 3.2.7 Feb 09, 2009: FDA Grants Clearance To Market A Modified Version Of GORE TAG Thoracic Endoprosthesis
      • 3.2.8 Feb 06, 2009: Biosense Webster Receives FDA Approval For Atrial Fibrillation Device
      • 3.2.9 Feb 06, 2009: FDA Grants Marketing Approval To NAVISTAR THERMOCOOL Catheter For Atrial Fibrillation
      • 3.2.10 Jan 28, 2009: TAXUS Liberte Drug-Eluting Stent System Of Boston Scientific Gains Japanese Approval
      • 3.2.11 Jan 07, 2009: AGA Medical's AMPLATZER Duct Occluder Receives Japanese Approval
      • 3.2.12 Dec 15, 2008: FDA Cleared Cross-Pilot Product Of Spectranetics Corporation
      • 3.2.13 Dec 09, 2008: ev3 Inc Receives FDA Clearance To Market EverCross Peripheral Angioplasty Balloons
      • 3.2.14 Dec 08, 2008: InspireMD's MGuard Coronary Stent System Approved In Israel
      • 3.2.15 Dec 02, 2008: SafeSept Transseptal Guidewire Receives US FDA Market Clearance
      • 3.2.16 Nov 20, 2008: FDA Advisory Panel Unanimously Recommends Approval Of NAVISTAR THERMOCOOL Catheter For Atrial Fibrillation
      • 3.2.17 Nov 10, 2008: FDA Approves Boston Scientific's Apex Over-The-Wire PTCA Dilatation Catheter
      • 3.2.18 Nov 10, 2008: Boston Scientific Receives FDA Approval For Apex Monorail PTCA Dilatation Catheter
      • 3.2.19 Oct 27, 2008: Cook Medical Receives CE Mark Approval For MiraFlex Microcatheter
      • 3.2.20 Oct 23, 2008: FDA Approves Boston Scientific's Carotid Artery Stent
      • 3.2.21 Oct 22, 2008: Endologix Announces FDA Approval Of IntuiTrak
      • 3.2.22 Oct 10, 2008: Boston Scientific Announces FDA Approval of Second-Generation TAXUS Liberte Drug-Eluting Stent
      • 3.2.23 Oct 03, 2008: Interrad Medical Receives FDA Clearance Of Catheter With Subcutaneous Securement System
      • 3.2.24 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Atom Stent System
      • 3.2.25 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Paclitaxel-Eluting Coronary Stent System For The Treatment Of In-Stent Restenosis
    • 3.3 Clinical Trials
      • 3.3.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.3.2 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.3.3 Jun 04, 2009: Cardiogenesis Corporation Presents Clinical Results Of PHOENIX Combination TMR Plus Stem Cell Delivery System At The International Society of Minimally Invasive Cardiothoracic Surgeons Annual Meeting
      • 3.3.4 Jun 01, 2009: Prescient Medical Announces SECRITT I Trial Results For vProtect Luminal Shield
      • 3.3.5 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.3.6 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.3.7 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.3.8 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.3.9 May 19, 2009: InfraReDx Combined Near-Infrared Spectroscopy And Ultrasound Imaging Catheter First Uses In Coronary Patients
      • 3.3.10 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.3.11 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.3.12 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.3.13 Apr 22, 2009: OrbusNeich Presents Results Of Genous Bio-Engineered R Stent In Higher Risk Patients
      • 3.3.14 Apr 09, 2009: ZEST Clinical Data Shows Better Clinical Outcomes Compare To TAXUS LIBERTE And ENDEAVOR Stents
      • 3.3.15 Apr 07, 2009: NMT Medical Presents Update On CLOSURE I Clinical Trial
      • 3.3.16 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.3.17 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.3.18 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.3.19 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.20 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.21 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.3.22 Mar 11, 2009: BridgePoint Medical Announces First US Clinical Case Completion Using CrossBoss And Stingray Devices In CTO Angioplasty Procedure
      • 3.3.23 Mar 04, 2009: Prescient Medical Announces Milestone Achievement In Clinical Studies Of vProtect Luminal Shield
      • 3.3.24 Feb 04, 2009: Two New Studies Reveals Clinical Effectiveness Of Cook Medical's Minocycline/Rifampin-Impregnated Catheters
      • 3.3.25 Feb 02, 2009: Medtronic Announces The Completion Of Patient Enrollment In Global Head-To-Head Stent-Safety Study
      • 3.3.26 Jan 26, 2009: Pivotal Two Year Results On XIENCE V Drug Eluting Stent Data Published
      • 3.3.27 Jan 22, 2009: Isotechnika Announces Enrollment Completion Of Its Partner Atrium's CONFIRM 1 Trial For Voclosporin Coated Coronary Stent System
      • 3.3.28 Jan 15, 2009: vProtect Luminal Shield Successfully Stabilizes Vulnerable Plaque
      • 3.3.29 Dec 18, 2008: Boston Scientific Initiates Carotid Stent Clinical Study
      • 3.3.30 Nov 11, 2008: Study Finds Catheter Ablation With The NAVISTAR THERMOCOOL Catheter Superior To Anti-Arrhythmic Drug Therapy For The Treatment Of Symptomatic, Paroxysmal Atrial Fibrillation
      • 3.3.31 Nov 07, 2008: Interim Analysis Of Data From e-HEALING Registry Of OrbusNeich's Genous Bio-Engineered R Stent To Be Presented At AHA Scientific Sessions 2008
      • 3.3.32 Oct 28, 2008: New Cappella Heart Stent Shows Promise
      • 3.3.33 Oct 21, 2008: MIV's VESTASYNC I Trial Preliminary Results Published
      • 3.3.34 Oct 16, 2008: Elixir Medical Corporation Announced Positive First-In-Man Results Of Novolimus Drug Eluting Coronary Stent System
      • 3.3.35 Oct 16, 2008: Danish Study Supports Efficacy Of Endeavor Stent
      • 3.3.36 Oct 16, 2008: OPEN I Study Demonstrates Safety Of The Stentys Stent At 30-Day Follow-Up Of 40 Patients
      • 3.3.37 Oct 15, 2008: HORIZONS AMI Trial Demonstrates Superior Outcomes With TAXUS Drug-Eluting Stents In Heart Attack Patients
      • 3.3.38 Oct 14, 2008: Endeavor vs. Taxus: Medtronic's Drug-Eluting Coronary Stent Linked To Fewer Heart Attacks At Two Years Post Implant
      • 3.3.39 Oct 14, 2008: Interim Analysis Of 12-Month Data From e-HEALING Registry Shows Good Safety And Efficacy In Real-World Use Of OrbusNeich's Genous Bio-engineered R stent
      • 3.3.40 Oct 13, 2008: New Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
      • 3.3.41 Oct 13, 2008: Custom NX Drug Eluting Stent System Continues To Demonstrate Favorable Outcomes In Challenging Patient Populations At One, Two And Three Years
      • 3.3.42 Oct 13, 2008: Abbott's XIENCE V Drug Eluting Stent Outperforms TAXUS In Key Efficacy And Safety Endpoints Out To Two Years
      • 3.3.43 Oct 13, 2008: 12-Month ATLANTA Trial Data Show Sustained Benefit Of Catania Stent In Treatment Of De Novo Coronary Lesions
      • 3.3.44 Oct 12, 2008: TAXUS Express Stent Shows Similarly Low Re-Intervention Rates In Patients With Diabetes Compared To Non-Diabetics In Arrive Registry Program
      • 3.3.45 Oct 12, 2008: Medtronic's Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile
      • 3.3.46 Oct 10, 2008: Cappella To Present Critical Data From Coronary Bifurcation Stent Studies At TCT 2008
      • 3.3.47 Oct 10, 2008: XTENT Announces Clinical Trial Data To Be Presented At Annual Meeting Of Transcatheter Cardiovascular Therapeutics Next Week
      • 3.3.48 Oct 09, 2008: Prescient Medical Presents Clinical And Preclinical Findings For vProtect Luminal Shield
      • 3.3.49 Oct 09, 2008: Prescient Medical Presents Clinical And Preclinical Findings For vPredict Optical Catheter System
      • 3.3.50 Oct 09, 2008: W. L. Gore & Associates Presents New Data And Clinical Updates At Transcatheter Cardiovascular Therapeutics Conference 2008
      • 3.3.51 Oct 08, 2008: Boston Scientific Completes Clinical Trial Enrollment For Third-Generation Drug-Eluting Stent
      • 3.3.52 Oct 08, 2008: NMT Medical Completes Enrollment In Landmark PFO/Stroke Clinical Trial
      • 3.3.53 Oct 07, 2008: Nexeon MedSystems Announces Enrollment Of First Patient In Feasibility Trial For Novel Prohealing Stent System
      • 3.3.54 Oct 07, 2008: SurModics Announces First Human Use Of Finale Prohealing Coating Technology On Nexeon MedSystems' PROTEX Coronary Stent System
      • 3.3.55 Oct 06, 2008: Data From Multiple Clinical Trials Of OrbusNeich's Genous Bio-engineered R stent To Be Presented At TCT 2008
      • 3.3.56 Sep 22, 2008: Sorin Group Announces First Patient Enrolment In The E-Optima Registry
      • 3.3.57 Sep 04, 2008: Clinical Data Indicate That Percutaneous Coronary Intervention With The CYPHER Sirolimus-Eluting Coronary Stent Is Comparable To Bypass Surgery In Key Safety Measures In Patients With Diabetes And Multi-Vessel Disease
      • 3.3.58 Sep 01, 2008: Biosensors DES Demonstrates Equivalent Safety And Efficacy To Industry Leading DES In First 'Real World, All Comers' Clinical Study
      • 3.3.59 Sep 01, 2008: SYNTAX Trial Reports Comparable Safety Outcomes For Patients Treated With TAXUS Express2 Stents Or Bypass Surgery
      • 3.3.60 Aug 28, 2008: The Cypher Sirolimus-Eluting Coronary Stent Outperforms The Taxus Stent In People With Diabetes
      • 3.3.61 Aug 26, 2008: Boston Scientific Corporation To Present Data From Landmark SYNTAX Clinical Trial
      • 3.3.62 Aug 10, 2008: InspireMD Announces Enrollment Of First Patients In The MGuard Acute Myocardial Infarction Clinical Trial Data Will Be Used To Confirm Initial Positive Results
      • 3.3.63 Aug 05, 2008: MIV Therapeutics Announces Excellent Safety And Efficacy Of VESTAsync Polymer-Free Drug-Eluting Stent At 12-Month Clinical Follow Up
      • 3.3.64 Jul 22, 2008: W. L. Gore & Associates Releases Interim Results Of GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface
      • 3.3.65 Jul 09, 2008: Abbott Begins Post-Approval Study Of XIENCE V Drug Eluting Stent
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Interventional Cardiology Clinical Trial By Equipment Type
    • Table 2: Interventional Cardiology Clinical Trials By Trial Phase and Trial Status
    • Table 3: Interventional Cardiology Pipeline Products By Development Stage
    • Table 4: Interventional Cardiology Pipeline Products By Therapy Area
    • Table 5: Interventional Cardiology Pipeline Products By News Summary
    • Table 6: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
    • Table 7: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
    • Table 8: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology